US20030003147A1 - Effer-vescent bisphosphonate formulation - Google Patents
Effer-vescent bisphosphonate formulation Download PDFInfo
- Publication number
- US20030003147A1 US20030003147A1 US10/191,669 US19166902A US2003003147A1 US 20030003147 A1 US20030003147 A1 US 20030003147A1 US 19166902 A US19166902 A US 19166902A US 2003003147 A1 US2003003147 A1 US 2003003147A1
- Authority
- US
- United States
- Prior art keywords
- sodium
- acid
- carbonate
- group
- alendronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Definitions
- This invention relates to pharmaceutical effervescent formulations of bisphosphonates, especially alendronate, and in particular, tablets and powders which effervesce when added to water.
- alendronate (4-amino-1-hydroxy-butylidene)bis-phosphonate
- etidronate (1-hydroxyethylidene)-bis-phosphonate
- neridronate (6-amino-1-hydroxyhexylidene)bis-phosphonate
- olpadronate [3-(dimethylamino)-1-hydroxy-propylidene]bis-phosphonate
- risedronate [0015] risedronate—[1-hydroxy-2-(3-pyridinyl)-ethylidene]bis-phosphonate;
- YH 529 [1-hydroxy-2-imidazo-(1,2a)pyridin-3-ylethylidene]bis-phosphonate
- zoledronate [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-phosphonate.
- Alendronate has been approved by various regulatory agencies, including the Food and Drug Administration in the United States as an oral osteoporosis treatment in post menopausal women.
- the currently marketed formulation is a tablet, and the patient is instructed to take the tablet with a full glass of water in the morning, at least a half hour prior to eating or drinking.
- certain side effects, including esophageal irritation and erosion have been reported if the tablet was not taken with enough water, or if the patient did not remain in an upright position for approximately one-half hour after taking the medication.
- the present invention is directed to an effervescent pharmaceutical formulation
- a bisphosphonate selected from the group consisting of: alendronate, cimadronate, clodronate, EB-1053, etidronate, ibandronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, YH 529, zoledronate, pharmaceutically acceptable salts and esters of the foregoing, and mixtures of the foregoing;
- an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;
- a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
- a binder selected from the group consisting of a non-reducing sugar such as mannitol, lactose, dextrose or sorbitol; polyvinyl pyrrolidone, or, sodium chloride, sodium benzoate and sodium sulfate;
- a lubricant selected from the group consisting of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and polyethylene glycol (PEG); and
- one or more additional agents selected from the group consisting of flavoring agents (such as orange and cherry) colorants, and sweeteners (including xylitol, aspartame or acesulfame K).
- flavoring agents such as orange and cherry
- sweeteners including xylitol, aspartame or acesulfame K.
- the present invention is also directed to an effervescent pharmaceutical formulation comprising alendronate or a pharmaceutically acceptable salt thereof as an active ingredient and
- an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;
- a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
- the acid source is present in at least an equivalent amount relative to the source of carbonate
- a binder selected from the group consisting of mannitol, sorbitol, polyvinyl pyrrolidone, lactose, sodium chloride sodium benzoate and sodium sulfate;
- a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate, powdered sodium bicarbonate and polyethylene glycol (PEG); and
- one or more additional agents selected from the group consisting of flavoring agents, particularly orange and cherry colorants, and sweeteners selected from the group consisting of xylitol, aspartame and acesulfame K.
- the effervescent pharmaceutical formulation of the present invention may be either a tablet or a powder.
- the tablet or powders are placed in an convenient amount of water to produce an effervescent liquid, and the patient drinks the effervescent liquid.
- the formulation is a tablet, wherein in one class the total weight of the tablet ranges from about 100 to about 50,000 mg. In another embodiment, the tablet weight ranges from about 1500 to about 32,500 mg and more particularly from about 20,800 to about 30,150 mg.
- bisphosphonate is intended to include the related bisphosphonic acids and salts, and various crystalline and amorphous forms.
- Alendronate includes the related bisphosphonic acid, and salt forms. It includes crystalline, hydrated crystalline, and amorphous forms of alendronate. It specifically includes alendronate sodium and alendronate monosodium trihydrate.
- the formulations of this invention have many distinct advantages.
- the patients drinks an effervescent liquid, which limits the amount of time in which the bisphosphonate is in contact with the esophageal tissue, thus minimizing the risk of irritation.
- the bioavailability of at least some of the bishosphonates, including alendronate is increased as a consequence of an excipient acting as a sequestering agent.
- the alendronate formulations are particularly advantageous in that alendronate is often prescribed to elderly patients who may experience difficulty in swallowing pills, but can more easily swallow a liquid formulation.
- the acid source is chosen from acid sources which are also sequestering agents. This is an important consideration because bisphosphonates, particularly alendronate, can be a potent sequestering agent of divalent cations, especially Ca 2+ and Mg 2+ . If either of these cations are present, the alendronate will sequester them, rendering the alendronate less bioavailable.
- Preferred acid sources which also act as a sequestering agent include citric acid and tartaric acid, and mixtures thereof. The excess citric acid or tartaric acid in the formulation binds the ions in issue and prevents their complexation with alendronate.
- the carbonate source should be chosen so that it does not contain divalent cations which could be sequestered by the bisphosphonate.
- Suitable carbonate sources are sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and sodium glycine carbonate.
- Preferred carbonate sources are sodium bicarbonate, sodium carbonate, and mixtures thereof.
- the acid source is present in an amount equal or greater than the carbonate source, on a molecular equivalent basis.
- the mole ratio of citric acid/bicarbonate is at least 1:3.
- there is an excess of citric acid as this not only helps to efficiently generate the effervescence, but also acts to sequester any ions which might otherwise complex with alendronate and the excess also acts as a flavor enhancer.
- the mole ratio of citric acid to bicarbonate ranges from 1:1 to 3:1.
- the binder may be a non-reducing sugar, such as mannitol, compressible lactose, dextrose or sorbitol. Alternatively, a polymer such as polyvinylpyrrolidone may be used. Other binders can include sodium chloride, sodium benzoate and sodium sulfate.
- the binder is usually present in approximately 3-10% of the tablet, and preferably about 5% (based on wt/wt), e.g. if the tablet weighs 1000 mg, the binder will be from about 30-100 mg, more preferably about 50 mg. If, however, a direct compression process is used to make the tablets, then a higher amount of binder is employed, preferably about 300-400 mg.
- the tablet should also contain a lubricant, which typically comprises about 0.5 to about 5% of the tablet on a wt/wt basis, and preferably about 1%.
- Preferred lubricants include powdered sodium benzoate, micronized polyethylene glycol 6000 and polyethylene glycol 8000, sodium lauryl sulfate, powdered sodium bicarbonate and L-leucine.
- the composition of the powder is similar to that of the tablet, except that the lubricant is generally present in a lesser amount (about less than one-half that in the tablet) and the binder should be chosen so that it is a dry binder.
- the powder is granulated.
- a colorant, flavoring agent such as orange or cherry or sweetner from the group xylitol, aspartame, or acesulfame K may be added to the formulation.
- a colorant, flavoring agent such as orange or cherry or sweetner from the group xylitol, aspartame, or acesulfame K
- Various methodologies for preparing the formulations of the current invention are illustrated in the examples below.
- Premix sodium benzoate with sodium bicarbonate and alendronate sodium Mix color with sodium carbonate. Place citric acid in a bowl of a suitable blender. Add the 2 mg water to the citric acid slowly and mix thoroughly to form a moist blend. Add to the blend, in sequence, while mixing, the sodium bicarbonate mix, and the sodium carbonate-color mix until uniformly distributed. Compress tablets using suitable size tooling. Cure the tablets, cool and package in aluminum foil.
- Blend alendronate sodium, citric acid and citrus flavor in a suitable blender Quickly add all of water and mix until a workable mass is formed. Granulate through a suitable screen using a granulator. Spread evenly on a paper-lined tray or a fluid bed dryer. Place a dried granulation in a suitable blender and add powder sodium bicarbonate. Mix well. Compress tablets using a suitable flat face beveled edge tooling. Package in aluminum foil or aluminum tubes.
- Part 1 Blend in a suitable mixer xylitol, alendronate and 400 mg sodium bicarbonate. Roller compact this mixture.
- Part 2 Blend in a suitable mixer sodium benzoate, citric acid, 900 mg sodium bicarbonate, color, flavor and sweetner; then roller compact this mixture.
- Part 3 Granulate Parts 1 and 2 through a suitable screen, add remaining powders and mix.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.
Description
- Not Applicable
- Not Applicable
- Not Applicable
- This invention relates to pharmaceutical effervescent formulations of bisphosphonates, especially alendronate, and in particular, tablets and powders which effervesce when added to water.
- There are numerous bisphosphonates which have been identified as having utility as pharmaceutical agents which inhibit bone resorption. These include:
- alendronate—(4-amino-1-hydroxy-butylidene)bis-phosphonate;
- cimadronate—[(cycloheptylamino)methylene]bis-phosphonate;
- clodronate—(dichloromethylene)-bis-phosphonate;
- EB-1053—[1-hydroxy-3-(1-pyrrolidinyl)-propylidene]bis-phosphonate;
- etidronate—(1-hydroxyethylidene)-bis-phosphonate;
- ibandronate—[1-hydroxy-3-(methylpentylamino)propylidene]bis-phosphonate;
- neridronate—(6-amino-1-hydroxyhexylidene)bis-phosphonate;
- olpadronate—[3-(dimethylamino)-1-hydroxy-propylidene]bis-phosphonate;
- pamidronate—(3-amino-1-hydroxypropylidene)bis-phosphonate;
- risedronate—[1-hydroxy-2-(3-pyridinyl)-ethylidene]bis-phosphonate;
- tiludronate—[[(4-chlorophenyl)thio]methylene]bis-phosphonate
- YH 529—[1-hydroxy-2-imidazo-(1,2a)pyridin-3-ylethylidene]bis-phosphonate; and
- zoledronate—[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-phosphonate.
- Alendronate has been approved by various regulatory agencies, including the Food and Drug Administration in the United States as an oral osteoporosis treatment in post menopausal women. The currently marketed formulation is a tablet, and the patient is instructed to take the tablet with a full glass of water in the morning, at least a half hour prior to eating or drinking. However, certain side effects, including esophageal irritation and erosion have been reported if the tablet was not taken with enough water, or if the patient did not remain in an upright position for approximately one-half hour after taking the medication.
- It would be desirable to develop a formulation which allows a bisphosphonate to be taken orally, yet avoids problems associated with prolonged contact between the medication and the esophagus.
- Not Applicable
- Not Applicable
- The present invention is directed to an effervescent pharmaceutical formulation comprising, as an active ingredient, a bisphosphonate selected from the group consisting of: alendronate, cimadronate, clodronate, EB-1053, etidronate, ibandronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, YH 529, zoledronate, pharmaceutically acceptable salts and esters of the foregoing, and mixtures of the foregoing;
- an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;
- a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
- a binder selected from the group consisting of a non-reducing sugar such as mannitol, lactose, dextrose or sorbitol; polyvinyl pyrrolidone, or, sodium chloride, sodium benzoate and sodium sulfate;
- a lubricant selected from the group consisting of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and polyethylene glycol (PEG); and
- optionally, one or more additional agents selected from the group consisting of flavoring agents (such as orange and cherry) colorants, and sweeteners (including xylitol, aspartame or acesulfame K).
- The present invention is also directed to an effervescent pharmaceutical formulation comprising alendronate or a pharmaceutically acceptable salt thereof as an active ingredient and
- an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;
- a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
- wherein the acid source is present in at least an equivalent amount relative to the source of carbonate;
- a binder selected from the group consisting of mannitol, sorbitol, polyvinyl pyrrolidone, lactose, sodium chloride sodium benzoate and sodium sulfate;
- a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate, powdered sodium bicarbonate and polyethylene glycol (PEG); and
- optionally, one or more additional agents selected from the group consisting of flavoring agents, particularly orange and cherry colorants, and sweeteners selected from the group consisting of xylitol, aspartame and acesulfame K.
- The effervescent pharmaceutical formulation of the present invention may be either a tablet or a powder. To use the formulation, the tablet or powders are placed in an convenient amount of water to produce an effervescent liquid, and the patient drinks the effervescent liquid.
- In one embodiment the formulation is a tablet, wherein in one class the total weight of the tablet ranges from about 100 to about 50,000 mg. In another embodiment, the tablet weight ranges from about 1500 to about 32,500 mg and more particularly from about 20,800 to about 30,150 mg.
- As used throughout this specification and claims, the term “bisphosphonate” is intended to include the related bisphosphonic acids and salts, and various crystalline and amorphous forms. “Alendronate” includes the related bisphosphonic acid, and salt forms. It includes crystalline, hydrated crystalline, and amorphous forms of alendronate. It specifically includes alendronate sodium and alendronate monosodium trihydrate.
- Methods for the preparation of bisphosphonates are well known in the art. Methods for the preparation of alendronate and alendronate sodium salt trihydrate are known. In particular, methods for the preparation of alendronate may be found in U.S. Pat. Nos. 4,922,007, 5,019,651 and 5,510,517, each of which is hereby incorporated by reference. The amount of active in the formulation based on a weight of alendronate will range from 1 to 80 mg, particularly 5-40 mg and more particularly 5-15 mg. Exemplary amounts of alendronate are 5, 10 and 40 mg.
- The formulations of this invention have many distinct advantages. First of all, the patients drinks an effervescent liquid, which limits the amount of time in which the bisphosphonate is in contact with the esophageal tissue, thus minimizing the risk of irritation. Secondly, the bioavailability of at least some of the bishosphonates, including alendronate is increased as a consequence of an excipient acting as a sequestering agent. Thirdly, the alendronate formulations are particularly advantageous in that alendronate is often prescribed to elderly patients who may experience difficulty in swallowing pills, but can more easily swallow a liquid formulation.
- In preferred embodiments of the invention the acid source is chosen from acid sources which are also sequestering agents. This is an important consideration because bisphosphonates, particularly alendronate, can be a potent sequestering agent of divalent cations, especially Ca2+ and Mg2+. If either of these cations are present, the alendronate will sequester them, rendering the alendronate less bioavailable. Preferred acid sources which also act as a sequestering agent include citric acid and tartaric acid, and mixtures thereof. The excess citric acid or tartaric acid in the formulation binds the ions in issue and prevents their complexation with alendronate.
- The carbonate source should be chosen so that it does not contain divalent cations which could be sequestered by the bisphosphonate. Suitable carbonate sources are sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and sodium glycine carbonate. Preferred carbonate sources are sodium bicarbonate, sodium carbonate, and mixtures thereof.
- In one aspect of this invention the acid source is present in an amount equal or greater than the carbonate source, on a molecular equivalent basis. Thus, when citric acid is the acid source and sodium bicarbonate is the carbonate source, the mole ratio of citric acid/bicarbonate is at least 1:3. In a particular class of this aspect there is an excess of citric acid, as this not only helps to efficiently generate the effervescence, but also acts to sequester any ions which might otherwise complex with alendronate and the excess also acts as a flavor enhancer. In an illustration of the excess acid source, the mole ratio of citric acid to bicarbonate ranges from 1:1 to 3:1. Where sodium carbonate is used as the source of carbonate an equal equivalent with citric acid will require a mole ratio of 2 moles citric acid to 3 moles carbonate. Analogous ratios can be calculated for any source of acid and carbonate, and of course the carbonate source may be present as a mixture of bicarbonate and carbonate.
- For patients who exhibit gastric irritation another aspect of this invention is to employ excess amounts of the carbonate source to provide an antacid effect to the formulation. Example 2 below demonstrates such a formulation.
- The binder may be a non-reducing sugar, such as mannitol, compressible lactose, dextrose or sorbitol. Alternatively, a polymer such as polyvinylpyrrolidone may be used. Other binders can include sodium chloride, sodium benzoate and sodium sulfate. The binder is usually present in approximately 3-10% of the tablet, and preferably about 5% (based on wt/wt), e.g. if the tablet weighs 1000 mg, the binder will be from about 30-100 mg, more preferably about 50 mg. If, however, a direct compression process is used to make the tablets, then a higher amount of binder is employed, preferably about 300-400 mg.
- The tablet should also contain a lubricant, which typically comprises about 0.5 to about 5% of the tablet on a wt/wt basis, and preferably about 1%. Preferred lubricants include powdered sodium benzoate, micronized polyethylene glycol 6000 and polyethylene glycol 8000, sodium lauryl sulfate, powdered sodium bicarbonate and L-leucine.
- For effervescent powder formulations, the composition of the powder is similar to that of the tablet, except that the lubricant is generally present in a lesser amount (about less than one-half that in the tablet) and the binder should be chosen so that it is a dry binder. In preferred formulations, the powder is granulated.
- Where desired a colorant, flavoring agent such as orange or cherry or sweetner from the group xylitol, aspartame, or acesulfame K may be added to the formulation. Various methodologies for preparing the formulations of the current invention are illustrated in the examples below.
- The following formulations and manufacturing procedures can be used for manufacture of effervescent tablets containing alendronate sodium.
- It should be understood that one skilled in this art will recognize equivalent formulations which are intended to be included with the scope of this invention.
-
Alendronate sodium 5-10 10 mg (in mg alendronate acid) Citric acid, anhydrous (granular) 600-700 650 mg Sodium bicarbonate (granular) 300-500 367 mg Sodium carbonate, anhydrous 20-60 40 mg Flavoring agent (optional) 10-50 25 mg Colorant (optional) 0-10 5 mg Sodium benzoate 5-15 7.5 mg Water 0-5 2 mg. - Premix sodium benzoate with sodium bicarbonate and alendronate sodium. Mix color with sodium carbonate. Place citric acid in a bowl of a suitable blender. Add the 2 mg water to the citric acid slowly and mix thoroughly to form a moist blend. Add to the blend, in sequence, while mixing, the sodium bicarbonate mix, and the sodium carbonate-color mix until uniformly distributed. Compress tablets using suitable size tooling. Cure the tablets, cool and package in aluminum foil.
-
Alendronate sodium 5-10 5 mg (in mg alendronate acid) or 10 mg Citric acid, anhydrous (granular) 450-650 590 mg Sodium bicarbonate (granular) 750-1000 850 mg Sodium bicarbonate, powder 50-150 87 mg Citrus flavor (optional) 0-50 25 mg Water 0-25 15 mg. - Blend alendronate sodium, citric acid and citrus flavor in a suitable blender. Quickly add all of water and mix until a workable mass is formed. Granulate through a suitable screen using a granulator. Spread evenly on a paper-lined tray or a fluid bed dryer. Place a dried granulation in a suitable blender and add powder sodium bicarbonate. Mix well. Compress tablets using a suitable flat face beveled edge tooling. Package in aluminum foil or aluminum tubes.
-
Alendronate sodium 10 mg (in mg alendronate acid) Mannitol, direct compression grade 165 mg Sodium bicarbonate 850 mg Citric acid 530 mg Sodium benzoate 15 mg - Mix alendronate sodium and sodium benzoate in a suitable mixer. Add mannitol and continue mixing till uniform. Add sequentially citric acid and sodium bicarbonate. Roller compact the powder mix followed by granulation using a suitable screen. Compress the granulation using a suitable tooling. Package the tablets in aluminum foil.
-
Alendronate sodium 2.5-10 10 mg (in mg alendronate acid) Citric acid, anhydrous (granular) 400-800 600 mg Sodium bicarbonate (granular) 1000-2000 1500 mg Sodium carbonate, anhydrous 20-80 40 mg Flavoring agent (optional) 0-50 25 mg Colorant (optional) 0-15 5 mg Sodium benzoate 25-175 150 mg Xylitol 100-300 200 mg Sweetner (aspartame) 1-10 2.5 mg - Part 1. Blend in a suitable mixer xylitol, alendronate and 400 mg sodium bicarbonate. Roller compact this mixture.
- Part 2. Blend in a suitable mixer sodium benzoate, citric acid, 900 mg sodium bicarbonate, color, flavor and sweetner; then roller compact this mixture.
- Part 3. Granulate Parts 1 and 2 through a suitable screen, add remaining powders and mix.
- Compress the granulation using a suitable tooling. Package the tablets in aluminum foil.
Claims (12)
1. An effervescent pharmaceutical formulation comprising as an active ingredient a bisphosphonate selected from the groups consisting of: alendronate, cimadronate, clodronate, EB-1053, etidronate, ibandronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, YH 529, zoledronate, pharmaceutically acceptable salts and esters of the foregoing, and mixtures of the foregoing; and
an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts; a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
a binder selected from the group consisting of a non-reducing sugar, polyvinyl pyrrolidone, sodium chloride, sodium benzoate and sodium sulfate;
a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and PEG; and
optionally, one or more additional agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
2. An effervescent pharmaceutical formulation according to claim 1 wherein the active ingredient comprises alendronate or a pharmaceutically acceptable salt thereof as an active ingredient and further comprising: an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts; a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
wherein the acid source is present in an equal or excess amount compared to the carbonate source, based on molecular equivalent amounts;
a binder selected from the group consisting of mannitol, sorbitol, polyvinyl pyrrolidone, lactose, sodium chloride, sodium benzoate and sodium sulfate;
a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and PEG; and
optionally, one or more additional agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
3. A formulation according to claim 2 wherein the amount of alendronate or salt thereof is from 1-80 mg.
4. A formulation according to claim 3 wherein the acid source is citric acid, tartaric acid or mixtures thereof.
5. A formulation according to claim 3 wherein the carbonate source is sodium bicarbonate, sodium carbonate, and mixtures thereof.
6. A formulation according to claim 5 wherein the mole ratio of citric acid to bicarbonate is from 1:1 to 1:3.
7. A formulation according to claim 5 wherein the binder is mannitol, lactose, dextrose or sorbitol.
8. A formulation comprising (in mg):
9. A formulation according to claim 8 , further comprising a flavoring agent or a colorant.
10. A formulation comprising (in mg):
11. A formulation comprising (in mg):
12. A formulation made by the process of combining:
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/191,669 US20030003147A1 (en) | 1996-05-17 | 2002-07-09 | Effer-vescent bisphosphonate formulation |
US10/751,791 US20040137058A1 (en) | 2002-07-09 | 2004-01-05 | Effervescent bisphosphonate formulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1788196P | 1996-05-17 | 1996-05-17 | |
US09/878,557 US20010041165A1 (en) | 1996-05-17 | 2001-06-11 | Effervescent bisphosphonate formulation |
US10/191,669 US20030003147A1 (en) | 1996-05-17 | 2002-07-09 | Effer-vescent bisphosphonate formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/878,557 Continuation US20010041165A1 (en) | 1996-05-17 | 2001-06-11 | Effervescent bisphosphonate formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/751,791 Continuation US20040137058A1 (en) | 2002-07-09 | 2004-01-05 | Effervescent bisphosphonate formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030003147A1 true US20030003147A1 (en) | 2003-01-02 |
Family
ID=21785061
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/848,460 Expired - Lifetime US5853759A (en) | 1996-05-17 | 1997-05-08 | Effervescent alendronate formulation |
US09/878,557 Abandoned US20010041165A1 (en) | 1996-05-17 | 2001-06-11 | Effervescent bisphosphonate formulation |
US10/191,669 Abandoned US20030003147A1 (en) | 1996-05-17 | 2002-07-09 | Effer-vescent bisphosphonate formulation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/848,460 Expired - Lifetime US5853759A (en) | 1996-05-17 | 1997-05-08 | Effervescent alendronate formulation |
US09/878,557 Abandoned US20010041165A1 (en) | 1996-05-17 | 2001-06-11 | Effervescent bisphosphonate formulation |
Country Status (2)
Country | Link |
---|---|
US (3) | US5853759A (en) |
ZA (1) | ZA974207B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267452A1 (en) * | 2010-05-28 | 2013-10-10 | Milliken & Company | Colored Speckles For Use In Granular Detergents |
US20160338905A1 (en) * | 2012-03-23 | 2016-11-24 | Raleigh Duncan | Low EMF Halogen Tube Heater |
US11219594B2 (en) | 2015-12-12 | 2022-01-11 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
US11576855B2 (en) | 2014-09-17 | 2023-02-14 | Steerlife India Private Limited | Effervescent composition and method of making it |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US20030091629A1 (en) | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
CZ289261B6 (en) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tablet that can be produced by direct tabletting, containing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid as active compound and process for producing thereof |
GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
CA2468687A1 (en) * | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
ES2448501T3 (en) | 2002-03-06 | 2014-03-14 | Effrx Pharmaceuticals Sa | Effervescent compositions comprising bisphosphonates |
EP1494683A1 (en) * | 2002-04-05 | 2005-01-12 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
US20040137058A1 (en) * | 2002-07-09 | 2004-07-15 | Katdare Ashok V. | Effervescent bisphosphonate formulation |
US20040138180A1 (en) * | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
TR200300510A2 (en) * | 2003-04-18 | 2004-11-22 | Sanovel �La� Sanay� Ve T�Caret A.�. | Dispersing alendronate microparticle formulation |
WO2005018640A1 (en) * | 2003-08-20 | 2005-03-03 | The Procter & Gamble Company | Kit for treatment of upper gastrointestinal tract conditions |
DE602004031462D1 (en) * | 2003-12-31 | 2011-03-31 | Cima Labs Inc | GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION |
WO2005065317A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
MXPA06007453A (en) | 2003-12-31 | 2007-01-31 | Cima Labs Inc | Effervescent oral opiate dosage form. |
US20060034921A1 (en) * | 2004-01-05 | 2006-02-16 | Katdare Ashok V | Effervescent bisphosphonate formulation |
US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
WO2005115342A1 (en) * | 2004-05-24 | 2005-12-08 | Nycomed Pharma As | Particulate comprising a calcium-containing compound and a sugar alcohol |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
KR100564628B1 (en) * | 2004-06-16 | 2006-03-28 | 삼성전자주식회사 | Split gate type flash mwmory device and method of manufacturing the same |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
US20070087052A1 (en) * | 2005-10-19 | 2007-04-19 | Katdare Ashok V | Effervescent bisphosphonate formulation |
WO2007124274A1 (en) * | 2006-04-21 | 2007-11-01 | The Uab Research Foundation | Treating neoplasms |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
US10456335B2 (en) * | 2008-04-02 | 2019-10-29 | 90 Seconds To Wow, Llc | Oral hygiene compositions and methods |
CA2820019A1 (en) | 2010-12-06 | 2012-06-14 | Effrx Pharmaceuticals Sa | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
TR201100151A2 (en) * | 2011-01-06 | 2012-07-23 | Bi̇lgi̇ç Mahmut | Ibandronate formulation. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1195993B (en) * | 1984-01-12 | 1988-11-03 | Gentili Ist Spa | PHARMACEUTICAL FORMS BASED ON DIPHOSPHONATES |
ES2074769T3 (en) * | 1991-07-01 | 1995-09-16 | Gergely Gerhard | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION WITH AT LEAST TWO DIFFERENT ACTIVE PRINCIPLES AND USE OF A PREPARATION OF THIS TYPE. |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
CA2151240A1 (en) * | 1992-12-23 | 1994-07-07 | Donna T. Whiteford | Biophosphonate/estrogen therapy for treating and preventing bone loss |
FR2703590B1 (en) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR. |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
US5656288A (en) * | 1995-06-08 | 1997-08-12 | Sanofi Winthrop, Inc. | Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions |
-
1997
- 1997-05-08 US US08/848,460 patent/US5853759A/en not_active Expired - Lifetime
- 1997-05-15 ZA ZA9704207A patent/ZA974207B/en unknown
-
2001
- 2001-06-11 US US09/878,557 patent/US20010041165A1/en not_active Abandoned
-
2002
- 2002-07-09 US US10/191,669 patent/US20030003147A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130267452A1 (en) * | 2010-05-28 | 2013-10-10 | Milliken & Company | Colored Speckles For Use In Granular Detergents |
US8921301B2 (en) * | 2010-05-28 | 2014-12-30 | Milliken & Company | Colored speckles for use in granular detergents |
US11649417B2 (en) | 2010-05-28 | 2023-05-16 | Milliken & Company | Colored speckles for use in granular detergents |
US20160338905A1 (en) * | 2012-03-23 | 2016-11-24 | Raleigh Duncan | Low EMF Halogen Tube Heater |
US11576855B2 (en) | 2014-09-17 | 2023-02-14 | Steerlife India Private Limited | Effervescent composition and method of making it |
US11219594B2 (en) | 2015-12-12 | 2022-01-11 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
ZA974207B (en) | 1997-11-17 |
US5853759A (en) | 1998-12-29 |
US20010041165A1 (en) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5853759A (en) | Effervescent alendronate formulation | |
CA2254060C (en) | Effervescent bisphosphonate formulation | |
ES2313735T5 (en) | Oral pharmaceutical preparation containing ibandronate | |
ES2255301T3 (en) | PROCEDURE FOR THE PREPARATION OF ORAL PHARMACEUTICAL COMPOSITIONS THAT INCLUDE BISPHOSPHONATES. | |
ES2253919T3 (en) | COMPOSITIONS CONTAINING DIFFOSPHONIC ACIDS. | |
CN1649598B (en) | High dose ibandronate formulation | |
US20060034921A1 (en) | Effervescent bisphosphonate formulation | |
US10420725B2 (en) | Solid dosage form of coated bisphosphonate particles | |
US9592195B2 (en) | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics | |
RU2134103C1 (en) | Tablet exhibiting improved bioavailability of biologically active substance and substance enhancing bioavailability | |
KR20060100395A (en) | Pharmaceutical formulation with improved stability | |
US20040137058A1 (en) | Effervescent bisphosphonate formulation | |
US20070087052A1 (en) | Effervescent bisphosphonate formulation | |
EP1378234A1 (en) | Effervescent bisphosphonate formulation | |
EP1820497A2 (en) | Effervescent bisphosphonate formulation | |
AU6315499A (en) | Effervescent bisphosphonate formulation | |
CA2622322A1 (en) | Bisphosphonate formulation | |
US20130022645A1 (en) | Pharmaceutical formulations of bisphosphonate with enhanced oral bioavailability | |
EP1491199A1 (en) | Pharmaceutical compositions of alendronate sodium trihydrate and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |